Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

PHASE1UnknownINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

August 31, 1999

Conditions
HIV Infections
Interventions
DRUG

Aldesleukin

Trial Locations (23)

11374

Anderson Clinical Research Inc, Rego Park

12208

Albany Med College, Albany

15221

Anderson Clinical Research, Pittsburgh

33133

Steinhart Medical Associates, Miami

33142

Specialty Med Care Ctrs of South Florida Inc, Miami

33146

Community AIDS Resource Inc, Coral Gables

35203

Sorra Research Ctr / Med Forum, Birmingham

60657

AIDS Research Alliance - Chicago, Chicago

Northstar Med Clinic, Chicago

74114

Associates in Med and Mental Health, Tulsa

75219

N Texas Ctr for AIDS & Clin Rsch, Dallas

77004

Gathe, Joseph, M.D., Houston

78705

Central Texas Clinical Research, Austin

80220

Denver Inf Disease Consultants, Denver

90211

Pacific Oaks Research, Beverly Hills

92101

St Lukes Medical Group, San Diego

92708

Orange County Ctr for Special Immunology, Fountain Valley

94118

Kaiser Foundation Hospital, San Francisco

97210

Research and Education Group, Portland

98101

Virginia Mason Med Ctr, Seattle

200091104

Dupont Circle Physicians Group, Washington D.C.

02115

Fenway Community Health Ctr, Boston

071032842

North Jersey Community Research Initiative, Newark

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Chiron Corporation

INDUSTRY

NCT00002449 - Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy | Biotech Hunter | Biotech Hunter